Neuroleptic-potentiating effect of α-methyl-p-tyrosine compared with haloperidol and placebo in a double-blind cross-over trial

G. Magelund, J. Gerlach, Daniel Casey

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The hypothesis that schizophrenia results from overactive dopaminergic influences suggests that reducing dopamine synthesis may increase the clinical effects of dopamine receptor blocking neuroleptic drugs. The neuroleptic potentiating role of α-methyl-para-tyrosine (AMPT), a tyrosine hydroxylase inhibitor, was compared with haloperidol and placebo in a double-blind cross-over trial. Both AMPT and haloperidol increased the anti-schizophrenic effect of neuroleptic treatment in reduced dose compared with placebo, though 2 patients relapsed during the AMPT period. Both drugs slightly increased extrapyramidal symptoms, but the effect was greater with haloperidol. The limited antipsychotic effect and the potential for aggravating neurological symptoms suggest that the combination of AMPT and neuroleptics does not offer a superior advantage to treating schizophrenia. AMPT, however, may still be used as a research tool in elucidating pathogenetic mechanisms.

Original languageEnglish (US)
Pages (from-to)185-189
Number of pages5
JournalActa Psychiatrica Scandinavica
Volume60
Issue number2
StatePublished - 1979
Externally publishedYes

Fingerprint

Haloperidol
Cross-Over Studies
Antipsychotic Agents
Tyrosine
Placebos
Schizophrenia
Dopamine Receptors
Tyrosine 3-Monooxygenase
Dopamine
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Neuroleptic-potentiating effect of α-methyl-p-tyrosine compared with haloperidol and placebo in a double-blind cross-over trial. / Magelund, G.; Gerlach, J.; Casey, Daniel.

In: Acta Psychiatrica Scandinavica, Vol. 60, No. 2, 1979, p. 185-189.

Research output: Contribution to journalArticle

@article{dcfe257c2cd54ad390984bf3768fcf56,
title = "Neuroleptic-potentiating effect of α-methyl-p-tyrosine compared with haloperidol and placebo in a double-blind cross-over trial",
abstract = "The hypothesis that schizophrenia results from overactive dopaminergic influences suggests that reducing dopamine synthesis may increase the clinical effects of dopamine receptor blocking neuroleptic drugs. The neuroleptic potentiating role of α-methyl-para-tyrosine (AMPT), a tyrosine hydroxylase inhibitor, was compared with haloperidol and placebo in a double-blind cross-over trial. Both AMPT and haloperidol increased the anti-schizophrenic effect of neuroleptic treatment in reduced dose compared with placebo, though 2 patients relapsed during the AMPT period. Both drugs slightly increased extrapyramidal symptoms, but the effect was greater with haloperidol. The limited antipsychotic effect and the potential for aggravating neurological symptoms suggest that the combination of AMPT and neuroleptics does not offer a superior advantage to treating schizophrenia. AMPT, however, may still be used as a research tool in elucidating pathogenetic mechanisms.",
author = "G. Magelund and J. Gerlach and Daniel Casey",
year = "1979",
language = "English (US)",
volume = "60",
pages = "185--189",
journal = "Acta Psychiatrica Scandinavica",
issn = "0001-690X",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Neuroleptic-potentiating effect of α-methyl-p-tyrosine compared with haloperidol and placebo in a double-blind cross-over trial

AU - Magelund, G.

AU - Gerlach, J.

AU - Casey, Daniel

PY - 1979

Y1 - 1979

N2 - The hypothesis that schizophrenia results from overactive dopaminergic influences suggests that reducing dopamine synthesis may increase the clinical effects of dopamine receptor blocking neuroleptic drugs. The neuroleptic potentiating role of α-methyl-para-tyrosine (AMPT), a tyrosine hydroxylase inhibitor, was compared with haloperidol and placebo in a double-blind cross-over trial. Both AMPT and haloperidol increased the anti-schizophrenic effect of neuroleptic treatment in reduced dose compared with placebo, though 2 patients relapsed during the AMPT period. Both drugs slightly increased extrapyramidal symptoms, but the effect was greater with haloperidol. The limited antipsychotic effect and the potential for aggravating neurological symptoms suggest that the combination of AMPT and neuroleptics does not offer a superior advantage to treating schizophrenia. AMPT, however, may still be used as a research tool in elucidating pathogenetic mechanisms.

AB - The hypothesis that schizophrenia results from overactive dopaminergic influences suggests that reducing dopamine synthesis may increase the clinical effects of dopamine receptor blocking neuroleptic drugs. The neuroleptic potentiating role of α-methyl-para-tyrosine (AMPT), a tyrosine hydroxylase inhibitor, was compared with haloperidol and placebo in a double-blind cross-over trial. Both AMPT and haloperidol increased the anti-schizophrenic effect of neuroleptic treatment in reduced dose compared with placebo, though 2 patients relapsed during the AMPT period. Both drugs slightly increased extrapyramidal symptoms, but the effect was greater with haloperidol. The limited antipsychotic effect and the potential for aggravating neurological symptoms suggest that the combination of AMPT and neuroleptics does not offer a superior advantage to treating schizophrenia. AMPT, however, may still be used as a research tool in elucidating pathogenetic mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=0018291452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018291452&partnerID=8YFLogxK

M3 - Article

C2 - 41413

AN - SCOPUS:0018291452

VL - 60

SP - 185

EP - 189

JO - Acta Psychiatrica Scandinavica

JF - Acta Psychiatrica Scandinavica

SN - 0001-690X

IS - 2

ER -